Update of HDL in atherosclerotic cardiovascular disease
Copyright © 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved..
Epidemiologic evidence supported an inverse association between HDL (high-density lipoprotein) cholesterol (HDL-C) levels and atherosclerotic cardiovascular disease (ASCVD), identifying HDL-C as a major cardiovascular risk factor and postulating diverse HDL vascular- and cardioprotective functions beyond their ability to drive reverse cholesterol transport. However, the failure of several clinical trials aimed at increasing HDL-C in patients with overt cardiovascular disease brought into question whether increasing the cholesterol cargo of HDL was an effective strategy to enhance their protective properties. In parallel, substantial evidence supports that HDLs are complex and heterogeneous particles whose composition is essential for maintaining their protective functions, subsequently strengthening the "HDL quality over quantity" hypothesis. The following state-of-the-art review covers the latest understanding as per the roles of HDL in ASCVD, delves into recent advances in understanding the complexity of HDL particle composition, including proteins, lipids and other HDL-transported components and discusses on the clinical outcomes after the administration of HDL-C raising drugs with particular attention to CETP (cholesteryl ester transfer protein) inhibitors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis - 35(2023), 6 vom: 06. Nov., Seite 297-314 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schoch, Leonie [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.arteri.2023.10.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364321318 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364321318 | ||
| 003 | DE-627 | ||
| 005 | 20231226095206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.arteri.2023.10.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1214.xml |
| 035 | |a (DE-627)NLM364321318 | ||
| 035 | |a (NLM)37940388 | ||
| 035 | |a (PII)S0214-9168(23)00096-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schoch, Leonie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Update of HDL in atherosclerotic cardiovascular disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Epidemiologic evidence supported an inverse association between HDL (high-density lipoprotein) cholesterol (HDL-C) levels and atherosclerotic cardiovascular disease (ASCVD), identifying HDL-C as a major cardiovascular risk factor and postulating diverse HDL vascular- and cardioprotective functions beyond their ability to drive reverse cholesterol transport. However, the failure of several clinical trials aimed at increasing HDL-C in patients with overt cardiovascular disease brought into question whether increasing the cholesterol cargo of HDL was an effective strategy to enhance their protective properties. In parallel, substantial evidence supports that HDLs are complex and heterogeneous particles whose composition is essential for maintaining their protective functions, subsequently strengthening the "HDL quality over quantity" hypothesis. The following state-of-the-art review covers the latest understanding as per the roles of HDL in ASCVD, delves into recent advances in understanding the complexity of HDL particle composition, including proteins, lipids and other HDL-transported components and discusses on the clinical outcomes after the administration of HDL-C raising drugs with particular attention to CETP (cholesteryl ester transfer protein) inhibitors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Aterosclerosis | |
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Cardiovascular disease | |
| 650 | 4 | |a Enfermedad cardiovascular | |
| 650 | 4 | |a HDL | |
| 650 | 4 | |a Terapia | |
| 650 | 4 | |a Therapy | |
| 650 | 7 | |a Cholesterol Ester Transfer Proteins |2 NLM | |
| 650 | 7 | |a Cholesterol |2 NLM | |
| 650 | 7 | |a 97C5T2UQ7J |2 NLM | |
| 650 | 7 | |a Lipoproteins, HDL |2 NLM | |
| 650 | 7 | |a Cholesterol, HDL |2 NLM | |
| 700 | 1 | |a Alcover, Sebastián |e verfasserin |4 aut | |
| 700 | 1 | |a Padró, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Aicha, Soumaya |e verfasserin |4 aut | |
| 700 | 1 | |a Mendieta, Guiomar |e verfasserin |4 aut | |
| 700 | 1 | |a Badimon, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Vilahur, Gemma |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis |d 1996 |g 35(2023), 6 vom: 06. Nov., Seite 297-314 |w (DE-627)NLM091632536 |x 1578-1879 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2023 |g number:6 |g day:06 |g month:11 |g pages:297-314 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.arteri.2023.10.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2023 |e 6 |b 06 |c 11 |h 297-314 | ||